Overview
Germ cell neoplasms encompass a spectrum of tumors arising from germ cells, including teratomas, seminomas, and non-seminomas, primarily affecting the testes but also occurring extracranially in children and adolescents. These tumors vary in maturity and differentiation, impacting treatment approaches and outcomes 136.Diagnosis
Histological Confirmation: Essential for diagnosis, distinguishing between mature and immature teratomas 1.
Imaging Studies: CT and MRI used to assess tumor extent and metastasis 12.
Markers: Alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH) levels are crucial for staging and monitoring response to therapy 16.
Immunohistochemistry: Useful for identifying specific differentiation patterns, such as trophoblastic elements in seminomas and entodermal differentiation in immature teratomas 6.Management
Surgical Resection: Primary treatment for localized disease, with high rates of upfront surgical success in both mature and immature teratomas 1.
Chemotherapy: High-dose carboplatin, etoposide, and ifosfamide (CEI) regimen for advanced or metastatic disease 5.
Thromboprophylaxis: Recommended to balance benefits and risks, avoiding central venous access devices when possible to reduce VTE risk 2.
Supportive Care: Includes hematopoietic growth factors and peripheral blood progenitor cell (PBPC) rescue to mitigate chemotherapy-induced toxicities 5.Special Populations
Pediatrics: Treatment outcomes vary; standardized protocols are needed, especially in low- and middle-income settings 1.
Comorbidities: Specific considerations for managing nephrotoxicity and hematologic recovery in patients with pre-existing renal conditions 5.Key Recommendations
Standardize Treatment Protocols: Develop and implement national treatment guidelines for extracranial germ cell tumors, particularly in pediatric populations to improve outcomes 1 (Evidence: Strong).
Avoid Central Venous Access Devices: Minimize use of central venous catheters during chemotherapy to reduce the risk of venous thromboembolic events 2 (Evidence: Moderate).
Thromboprophylaxis Tailored to Risk: Prescribe thromboprophylaxis based on individual patient risk assessment to balance benefits and risks 2 (Evidence: Moderate).
Monitor Nephrotoxicity Closely: Regularly assess renal function in patients receiving high-dose carboplatin regimens to manage complications effectively 5 (Evidence: Moderate).References
1 Hendricks M, Cois A, Geel J, van Heerden J, Naidu G, Plessis JD et al.. Extracranial germ cell tumours: Mature and immature (1990-2015). First report by the South African Association of Paediatric Haematology Oncology (SAAPHO). Pediatric blood & cancer 2024. link
2 Fankhauser CD, Oldenburg J, Albers P, Algaba F, Bokemeyer C, Boormans JL et al.. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. European urology 2021. link
3 Trabert B, Sigurdson AJ, Sweeney AM, Amato RJ, Strom SS, McGlynn KA. Baldness, acne and testicular germ cell tumours. International journal of andrology 2011. link
4 Hanazawa M, Kawasaki I, Kunitomo H, Gengyo-Ando K, Bennett KL, Mitani S et al.. The Caenorhabditis elegans eukaryotic initiation factor 5A homologue, IFF-1, is required for germ cell proliferation, gametogenesis and localization of the P-granule component PGL-1. Mechanisms of development 2004. link
5 Beyer J, Rick O, Weinknecht S, Kingreen D, Lenz K, Siegert W. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone marrow transplantation 1997. link
6 Hustin J, Reuter AM, Franchimont P. Immunohistochemical localization of HCG and its subunits in testicular germ cell tumours. Virchows Archiv. A, Pathological anatomy and histopathology 1985. link